Perfil
Tom Willis is currently a Director at SonoThera, Inc. He was previously a Director at Adaptive Biotechnologies Corp.
Cargos activos de Tom Willis
| Empresas | Cargo | Inicio |
|---|---|---|
SonoThera, Inc.
 SonoThera, Inc. Pharmaceuticals: OtherHealth Technology SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Tom Willis.
| Empresas | Cargo | Fin |
|---|---|---|
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Director/Miembro de la Junta | 01/01/2019 |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ADAPTIVE BIOTECHNOLOGIES CORPORATION | Health Technology |
| Empresas privadas | 1 |
|---|---|
SonoThera, Inc.
SonoThera, Inc. Pharmaceuticals: OtherHealth Technology SonoThera, Inc. is a biotechnology company founded by Michael H. Davidson, Kenneth P. Greenberg, and Steve Feinstein. The company is based in South San Francisco, CA. The company is dedicated to treating the root cause of human disease through genetic therapy. SonoThera is developing an ultrasound-guided, nonviral gene therapy platform and treatments designed to provide patients with the next generation of safe and effective genetic medicines. The platform utilizes sonoporation, a microbubble-mediated biophysical process to non-invasively deliver genetic payloads selectively targeting a wide range of organs within the body. Kenneth P. Greenberg has been the CEO since incorporation. | Health Technology |
- Bolsa de valores
- Insiders
- Tom Willis
